Research programme: lung cancer therapeutics - OncoTherapy Science/Yakult Honsha
Latest Information Update: 27 Nov 2007
At a glance
- Originator OncoTherapy Science; Yakult Honsha
- Class Antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Lung cancer
Most Recent Events
- 03 May 2004 Preclinical trials in Lung cancer in Japan (unspecified route)